CardioDx, Inc.'s Corus CAD Gene Expression Test Performs Equally Well in Both Women and Men for the Assessment of Obstructive Coronary Artery Disease, Study Shows
7/31/2012 10:02:52 AM
PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the American Heart Journal. The paper, titled “A Gender Specific Blood-Based Gene Expression Score for Assessing Obstructive Coronary Artery Disease in Non-Diabetic Patients: Results of the PREDICT Trial,” reported the performance of the company’s Corus® CAD gene expression test for the assessment of obstructive coronary artery disease (CAD) in men and women presenting with typical and atypical symptoms suggestive of obstructive CAD. The article is in press (available online now) and will appear in the September issue of the journal.